AIHTA - Publications - Search - Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer

Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.

[thumbnail of DSD_HSO_Nr.16.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Cabazitaxel, a new molecular entity, is indicated as 2nd-line therapy for patients with metastatic castration- resistant prostate cancer. Cabazitaxel is licensed in the U.S. and received a positive opinion of the EMA’s Committee for Medicinal Products for Human Use based on the results of a phase III trial which investigated cabazitaxel + prednisone in comparison to mitoxantrone + prednisone. Median overall survival showed a statistically significant improvement for patients treated with cabazitaxel in comparison to mitoxantrone (HR=0.70, p<0.0001). However, the difference was only 2.4 months in comparison to a drug with an unknown impact on survival itself. Also, as this new therapy is associated with frequent and sometimes life-threatening adverse events, data on quality-of-life, which are still missing, are of utmost interest. Further questions which need to be addressed are the efficacy of cabazitaxel in comparison to docetaxel in the 1st-line setting.
In summary, reliable estimates of the drug’s true significance are not possible to date.

Item Type:DSD: Horizon Scanning in Oncology
Additional Information:This report is the product of a collaboration with the HTA Center Bremen (Germany), an offspring of the European network for Health Technology Assessment (EUnetHTA) Project that was supported by a grant from the European Commission. The responsibility lies with the author(s)solely, the European Commission is not responsible for any use that may be made of the information contained therein.
Keywords:Prostate cancer, chemotherapy, hormone-refractory, castration-resistant, 2nd-line, second-line, Cabazitaxel, Jevtana
Subjects:WJ Urogenital system > WJ 700-875 Male genitalia
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:DSD: Horizon Scanning in Oncology 16
Deposited on:12 Apr 2011 14:54
Last Modified:15 Jul 2020 17:45

Repository Staff Only: item control page